2. Academic Validation
  3. Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists

Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists

  • Bioorg Med Chem Lett. 2010 Aug 1;20(15):4491-5. doi: 10.1016/j.bmcl.2010.06.034.
Hai-Yun Xiao 1,  Aaron Balog,  Ricardo M Attar,  David Fairfax,  Linda B Fleming,  Christian L Holst,  Gregory S Martin,  Lana M Rossiter,  Jing Chen,  Mary-Ellen Cvjic,  Janet Dell-John,  Jieping Geng,  Marco M Gottardis,  Wen-Ching Han,  Andrew Nation,  Mary Obermeier,  Cheryl A Rizzo,  Liang Schweizer,  Thomas Spires Jr,  Weifang Shan,  Ashvinikumar Gavai,  Mark E Salvati,  Gregory Vite
Affiliations

Affiliation

  • 1 Bristol-Myers Squibb Company, Research and Development, Princeton, NJ 08543-4000, USA. haiyun.xiao@bms.com
PMID: 20584610 DOI: 10.1016/j.bmcl.2010.06.034
Abstract

A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the Androgen Receptor was investigated and several were found to have potent activity in vitro and in vivo.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z